Young Soo Rho
Young Soo Rho
Hospitalist, The Queen's Medical Center. Assistant Professor University of Hawaii
Verified email at
Cited by
Cited by
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet, 2020
Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review
K Polom, D Murawa, Y Rho, P Nowaczyk, M Hünerbein, P Murawa
Cancer 117 (21), 4812-4822, 2011
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ...
JAMA oncology 7 (8), 1167-1175, 2021
Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green–human serum albumin in comparison with gamma emitting radioactive …
K Polom, D Murawa, P Nowaczyk, YS Rho, P Murawa
European Journal of Surgical Oncology (EJSO) 38 (2), 137-142, 2012
Comparing clinical characteristics and outcomes of young-onset and late-onset colorectal cancer: an international collaborative study
YS Rho, M Gilabert, K Polom, A Aladashvili, K Kopeckova, V Megdanova, ...
Clinical colorectal cancer 16 (4), 334-342, 2017
Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1
W Polom, M Markuszewski, YS Rho, M Matuszewski
Central European journal of urology 67 (2), 142, 2014
Racial disparities in COVID-19 outcomes among black and white patients with cancer
J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ...
JAMA network open 5 (3), e224304-e224304, 2022
Adjuvant therapy for stages II and III colon cancer: Risk stratification, treatment duration, and future directions
U Bender, YS Rho, I Barrera, S Aghajanyan, J Acoba, P Kavan
Current Oncology 26 (s1), 43-52, 2019
Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19
AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ...
JAMA network open 4 (11), e2134330-e2134330, 2021
Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2
W Polom, M Markuszewski, YS Rho, M Matuszewski
Central European journal of urology 67 (3), 310, 2014
Skin melanoma sentinel lymph node biopsy using real‐time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin
K Polom, D Murawa, YS Rho, A Spychala, P Murawa
British Journal of Dermatology 166 (3), 682-683, 2012
Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19
Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ...
JAMA oncology 9 (1), 128-134, 2023
Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer
J McLean, YS Rho, G Kuruba, A Mamo, M Gilabert, T Kavan, L Panasci, ...
Clinical colorectal cancer 15 (2), 135-140, 2016
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
M Gilabert, B Chanez, YS Rho, M Giovanini, O Turrini, G Batist, P Kavan, ...
Medicine 96 (16), e6544, 2017
Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization
TY Wang, AS Wahed, A Morris, LB Kreuziger, JG Quigley, GA Lamas, ...
Annals of internal medicine 176 (4), 515-523, 2023
Quantifying treatment delays in adolescents and young adults with cancer at McGill University
Y Xu, M Stavrides-Eid, A Baig, M Cardoso, YS Rho, WM Shams, A Mamo, ...
Current Oncology 22 (6), 470-477, 2015
A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance
M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ...
Cancer cell 38 (6), 761-766, 2020
Patterns and predictors of emergency department visits among older patients after breast cancer surgery: a population-based cohort study
T Westley, A Syrowatka, D Henault, YS Rho, F Khazoom, SL Chang, ...
Journal of geriatric oncology 9 (3), 204-213, 2018
Targeted therapies provide treatment options for poorly differentiated pancreatic neuroendocrine carcinomas
M Gilabert, YS Rho, P Kavan
Oncology 92 (3), 170-172, 2017
Progression pattern and adverse events with bevacizumab in glioblastoma
A Mamo, A Baig, M Azam, YS Rho, S Sahebjam, T Muanza, S Owen, ...
Current Oncology 23 (5), 468-471, 2016
The system can't perform the operation now. Try again later.
Articles 1–20